← Leaderboards
Yong Lu
Methodist Hospital Research Institute
$10,592,811
Attributed
$11,725,853
Total exposure
8
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.7M · FY2015–25$5M$3.8M$2.5M$1.3M$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,725,853 · 8
By mechanism
R01$9,005,509 · 5
R37$1,788,794 · 1
R00$747,000 · 1
K99$184,550 · 1
Top collaborators
- Dawen Zhao5 shared
Others in their field
Top investigators on “Neoplastic Cell”
- David Heimbrook · Leidos Biomedical Research, Inc.$139,710,838
- Gregory H Reaman · National Childhood Cancer Foundation$31,993,642
- Bruce W Stillman · Cold Spring Harbor Laboratory$25,455,900
- Ralph Parchment · Leidos Biomedical Research, Inc.$25,266,647
- Andrea Califano · Columbia University Health Sciences$22,374,316
- Wendell A Lim · University Of California, San Francisco$22,334,734
Research focus
Neoplastic CellT-LymphocyteTumorIn VivoMalignant NeoplasmsMediatingCellsSignal TransductionAntigensTumor ImmunityTumor AntigensAdoptive Cell TransfersResponseFoundationsClinical TrialsSolid NeoplasmMouse ModelRelapseImmuneProductionMelanomaImmunityImmunotherapyRecurrence
Grant awards (31)
Decoupling acute toxicities and antitumor efficacy in adoptive cell therapy$593,810
R01 · FY2025 · CA · contact PI
Induction of autosis to overcome resistance in adoptive cell therapy for solid tumors$568,682
R01 · FY2025 · CA · contact PI
Intrapleural immunotherapeutic nanoparticles for MPE treatment$458,346
R01 · FY2025 · CA
The Unique Roles of Tumor-Specific Th9 Cells for Solid Tumor Eradication$396,737
R01 · FY2025 · CA · contact PI
Eradication of Escaped Variant Tumor Cells for Cancer Immunotherapy$388,825
R01 · FY2025 · CA · contact PI
Decoupling acute toxicities and antitumor efficacy in adoptive cell therapy$600,313
R01 · FY2024 · CA · contact PI
Induction of autosis to overcome resistance in adoptive cell therapy for solid tumors$539,865
R01 · FY2024 · CA · contact PI
Intrapleural immunotherapeutic nanoparticles for MPE treatment$435,429
R01 · FY2024 · CA
The Unique Roles of Tumor-Specific Th9 Cells for Solid Tumor Eradication$376,900
R01 · FY2024 · CA · contact PI
Eradication of Escaped Variant Tumor Cells for Cancer Immunotherapy$369,383
R01 · FY2024 · CA · contact PI
P38 MAPK is a molecular switch that controls the acquired resistance in adoptive cell therapy$350,064
R37 · FY2024 · CA · contact PI
Induction of autosis to overcome resistance in adoptive cell therapy for solid tumors$583,266
R01 · FY2023 · CA · contact PI
Intrapleural immunotherapeutic nanoparticles for MPE treatment$449,180
R01 · FY2023 · CA
The Unique Roles of Tumor-Specific Th9 Cells for Solid Tumor Eradication$388,802
R01 · FY2023 · CA · contact PI
Eradication of Escaped Variant Tumor Cells for Cancer Immunotherapy$381,049
R01 · FY2023 · CA · contact PI
P38 MAPK is a molecular switch that controls the acquired resistance in adoptive cell therapy$361,117
R37 · FY2023 · CA · contact PI
Intrapleural immunotherapeutic nanoparticles for MPE treatment$449,180
R01 · FY2022 · CA
The Unique Roles of Tumor-Specific Th9 Cells for Solid Tumor Eradication$403,102
R01 · FY2022 · CA · contact PI
Eradication of Escaped Variant Tumor Cells for Cancer Immunotherapy$393,863
R01 · FY2022 · CA · contact PI
P38 MAPK is a molecular switch that controls the acquired resistance in adoptive cell therapy$368,487
R37 · FY2022 · CA · contact PI
Intrapleural immunotherapeutic nanoparticles for MPE treatment$473,950
R01 · FY2021 · CA
The Unique Roles of Tumor-Specific Th9 Cells for Solid Tumor Eradication$381,210
R01 · FY2021 · CA · contact PI
Eradication of Escaped Variant Tumor Cells for Cancer Immunotherapy$373,617
R01 · FY2021 · CA · contact PI
P38 MAPK is a molecular switch that controls the acquired resistance in adoptive cell therapy$230,563
R37 · FY2021 · CA · contact PI
P38 MAPK is a molecular switch that controls the acquired resistance in adoptive cell therapy$124,000
R37 · FY2021 · CA · contact PI
P38 MAPK is a molecular switch that controls the acquired resistance in adoptive cell therapy$354,563
R37 · FY2020 · CA · contact PI
Th9 cells as a promising effector T-cell subset for cancer therapy$249,000
R00 · FY2019 · CA · contact PI
Th9 cells as a promising effector T-cell subset for cancer therapy$249,000
R00 · FY2018 · CA · contact PI
Th9 cells as a promising effector T-cell subset for cancer therapy$249,000
R00 · FY2017 · CA · contact PI
Th9 cells as a promising effector T-cell subset for cancer therapy$92,275
K99 · FY2016 · CA · contact PI
Th9 cells as a promising effector T-cell subset for cancer therapy$92,275
K99 · FY2015 · CA · contact PI